Selank: What the Research Shows
Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences, structurally derived from tuftsin — a naturally occurring immunomodulatory peptide. Sequence modifications were introduced to improve its stability. Research on Selank centers on two intersecting areas: anxiety-related behavior and brain-derived neurotrophic factor (BDNF), a protein involved in neuronal survival and synaptic plasticity.
Anxiolytic Activity
A study using an unpredictable chronic mild stress model in rats — a standard method for modeling anxiety-like behavior — tested Selank both alone and in combination with diazepam, a conventional benzodiazepine anxiolytic. Researchers found that Selank enhanced diazepam’s anxiety-reducing effect when the two were administered together, pointing to a possible complementary mechanism between the peptide and traditional anxiolytic pathways (Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats, Behavioral Neurology, 2017).
BDNF and Memory Protection
A separate study examined Selank’s effect on memory in rats exposed to chronic ethanol over 30 weeks — a model used to study alcohol-related cognitive decline. Researchers found that Selank prevented the memory and attention disturbances that typically develop during alcohol withdrawal, and in ex vivo brain tissue analysis, found that Selank normalized ethanol-induced changes in BDNF levels in the hippocampus and prefrontal cortex — two brain regions central to memory formation (Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content in the Hippocampus and Prefrontal Cortex in Rats, Bulletin of Experimental Biology and Medicine, 2019).
Molecular Mechanism
A more mechanistic study looked at gene expression directly, examining how Selank affects the GABAergic system — the brain’s primary inhibitory signaling pathway, and the same general system targeted by benzodiazepine medications. Researchers found that Selank administration altered the expression of specific genes involved in GABAergic neurotransmission, offering a possible molecular explanation for its observed anxiolytic effects in behavioral studies (Kolomin et al., Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission, Frontiers in Pharmacology, 2016).
Proposed Mechanism
Taken together, research on Selank points to a few interconnected pathways:
- BDNF regulation — rather than simply elevating BDNF, research suggests Selank may work to normalize BDNF levels that have been disrupted by a stressor (such as chronic alcohol exposure)
- GABAergic gene expression — altering expression of genes in the brain’s primary inhibitory signaling system, mechanistically distinct from how benzodiazepines act directly on GABA receptors
- Enkephalin system interaction — Selank has been studied for its effect on enkephalin-degrading enzymes, which may extend the activity of the body’s own natural opioid-like peptides involved in stress and mood regulation
Current State of the Evidence
It’s important to be direct about where this research stands: Selank has a longer history of study in Russia than in Western research institutions, and the studies above are preclinical, conducted entirely in rodent models. Selank has not been evaluated in large-scale, internationally peer-reviewed randomized controlled human trials, and it is not approved by the FDA or EMA.
Explore our Selank research product:
View SelankThis overview reflects published preclinical research. Products offered by Core Molecular Solutions are intended for laboratory research purposes only and are not for human or veterinary use.